Apollo Neuro research

Read the research behind the results

Woman using Apollo and iPhone and looking at her Apollo sleep data

The Apollo wearable鈥檚 efficacy has been validated in a number of independent and university-led trials, and there are more studies in progress focused on stress-related conditions. The Apollo Neuro team is excited to share these promising results in our mission to help people take control of their stress and live healthier, happier lives.

7
completed clinical trials
14
ongoing clinical trials

馃帠锔廤e are proud to share that two of our studies are double-blind randomized placebo controlled crossover trials.

What does that mean? A double-blind randomized placebo-controlled crossover trial is the gold-standard in scientific methodology. These studies are accepted as producing results that are untainted by bias. The sample size in these rigorous trials are more powerful than a study that simply compares two groups. Each subject in a double-blind randomized placebo-controlled crossover trial is exposed to every condition of the trial multiple times.

Apollo improves:
Sleep
Focus
Calm
Recovery
Heart rate variability

Completed studies and preliminary results

NEW: Apollo vibrations improve HRV in a double-blind randomized placebo-controlled crossover trial

Partner

University of Pittsburgh

Results

Statistically significant increase in HRV

Population

University of Pittsburgh club and varsity athletes

Sample size

22

Primary outcomes

Improved HRV, Faster recovery

馃帠锔廌ouble-blind randomized placebo controlled crossover trial


Real-world observational study of Apollo to improve sleep and cardiovascular metrics

Preliminary results

Those who use the Apollo wearable consistently (3+ hours a day, 5+ days a week, during the day and night) over 3 months see the biggest improvements in sleep and cardiovascular recovery metrics.

Up to 19% increase in deep sleep
Up to 14% increase in REM sleep
Up to 6% increase in total sleep time
Up to 4% decrease in resting heart rate
Up to 11% increase in HRV

Population

Apollo wearable users (18+)

Sample size

582

Primary outcomes

Sleep quality and cardiovascular metrics (heart rate, HRV) as measured by Oura Ring

*This study is sponsored by Apollo Neuro


Double-blind randomized placebo-controlled crossover study of Apollo to improve HRV and cognitive performance

Partner

University of Pittsburgh

Results

In a double-blind randomized placebo-controlled crossover clinical trial, Apollo vibrations improved heart rate variability (HRV) and cognitive performance under stress.

25% increase in focus and concentration, on average
10% increase in HRV, on average

Population

Healthy adults (18+)

Sample size

38

Primary outcomes

Cognitive performance

Secondary outcomes

HRV, self-reported stress, pupil dilation, galvanic skin response, respirations, EEG

馃帠锔廌ouble-blind randomized placebo controlled crossover trial


Open-label trial of Apollo to improve access to meditative states

Partner

University of Pittsburgh

Results

Both experienced and naive meditators achieve significantly deeper meditative states with the Apollo wearable.

50% faster access to meditative states for non-meditators, on average

Population

Healthy adults (18+)

Sample size

50 (25 experienced meditators, 25 without meditation experience)

Primary outcomes

Positive affect, HRV

Secondary outcomes

Negative affect, task performance, EEG


Pilot study of Apollo in nurses to reduce stress and signs of burnout

Partner

Skilled nursing facility 鈥 Pittsburgh, PA

Results

In an open-label evaluation to improve employee wellness and quality of care in nursing home staff, the Apollo wearable reduced stress in nursing staff by up to 40% in two weeks.

40% less stress and feelings of anxiety, on average

Population

Nurses

Sample size

12

Primary outcome

Quality of life, mood, and stress symptoms


Pilot study of Apollo to improve focus and calm in children with ADHD and anxiety disorders

Partner

Children鈥檚 Integrated Center for Success (CICS)

Results

Neurodevelopmental pediatrics pilot study shows improvement in mood, behavior, engagement, and stress reduction in children and adolescents with anxiety and ADHD.

100% of patients showed improvements in mood and behavior
9 out of 10 patients showed improvement in engagement
50% reduction in stress score

Population

Pediatrics age 7-17 across a breadth of diagnostic categories, like mood and anxiety disorders, as well as impulse control, autism, and ADHD

Sample size

15

Primary outcome

Mood & behavior, stress reduction, engagement


Pilot study of Apollo to improve athletic performance, recovery, and HRV

Partner

Division 1 University Athletics Department

Results

In a study of collegiate athletes, the Apollo wearable improved heart rate variability (HRV), athletic performance and recovery.

10% faster physical recovery, on average
10% increase in HRV, on average

Population

Collegiate athletes (18+)

Sample size

40

Primary outcomes

Athletic performance and recovery, cardiovascular metrics (HRV, heart rate)


Open-label trial of Apollo to improve symptoms in patients with PTSD

Partner

University of Pittsburgh

Results

Apollo use over 2 weeks significantly improved symptom scores in subjects with PTSD

Population

Adults with diagnosed PTSD (Ages 18-58)

Sample Size

16

Primary Outcomes

Change in PTSD symptoms and HRV before and after Apollo use.

Studies in progress

Transcranial Magnetic Stimulation (TMS) Therapy for Treatment-Resistant Depression and PTSD

Partner

Mytransformations, LLC

Status

IRB approved, not recruiting

Sample Size

100

Population

Ages 18+ clinically diagnosed for at least one of the following conditions: Major Depressive Disorder (MDD), recurrent, Treatment-resistant depression (TRD), Post-traumatic stress disorder (PTSD). Have been prescribed transcranial magnetic stimulation (TMS)

Primary Outcomes

Examine whether the Apollo device can help improve treatment response rates in patients with TRD and/or PTSD in undergoing TMS compared to TMS alone.

Secondary Outcomes

Examine whether use of the Apollo device after completion of the TMS therapy retains or improves patient outcomes.


A Wearable Wrist-Worn Nerve Stimulator for Remediating Autonomic Dysfunction Associated Chronic Migraine/Headache and Mood Disturbance in Adolescents

Partner

University of South Carolina

Status

IRB approved, not recruiting

Sample Size

60

Population

Clinic patients (ages 10+) who the clinicians have diagnosed with chronic headache/migraine and deemed suitable for the use of the device

Primary Outcomes

Evaluate the effectiveness of the Apollo Device for remediating clinical symptoms including pain, anxiety, depression and sleep disturbance via comparison of scores at initial evaluation and follow-up appointments.


Acute Nerve Stimulation for Enhancing Human and Cognitive Performance

Partner

University of South Carolina

Status

IRB approved, not recruiting

Sample Size

35

Population

Recreationally active adults (age 18-35). ROTC from The University of South Carolina and Benedict College

Primary Outcomes

The purpose of this within subject, repeated measures study is to evaluate the effectiveness of Apollo鈥檚 stimulation compared to sham stimulation. The main outcome of interest is the Apollo Neuro Device鈥檚 influence on physiological function to mediate human performance and cognition. Physiological function will be derived from metrics of heart rate variability and blood-based biomarkers, whilst human performance will be evaluated using tasks that assess cognitive domains of executive function, reaction time, and memory.


Long Covid

Partner

The Board of Medicine

Status

IRB approved, recruiting

Sample Size

TBD

Population

Age 18 or over. Currently experiencing symptoms related to post-COVID conditions

Primary Outcomes

Evaluate the impact of Apollo wearable use on symptomology in people experiencing post-COVID conditions.

Secondary Outcomes

Evaluate the impact of Apollo wearable use on quality of life in people experiencing post-COVID conditions.


Ketamine Therapy First Responder Study

Partner

Pamela Kryskow

Status

IRB approved, recruiting

Sample Size

TBD

Population

Age 18 or over. First responders enrolled in ketamine therapy.

Primary Outcomes

To evaluate the effect of the Apollo Neuro device on treatment resistant anxiety disorders in participants in the 12 week Ketamine Assisted Therapy program (RTT-KAT).

Secondary Outcomes

To determine whether the Apollo Neuro device enhances the success of the RTT-KAT treatment program for participants with treatment resistant anxiety disorders.


Retrospective Oura Study

Partner

Apollo Neuroscience (internal study)

Status

IRB approved, not recruiting

Sample Size

TBD

Population

At least one day of summary data from the Oura ring prior to Apollo wearable use; and, at least one day of summary data from the Oura ring after Apollo wearable use.

Primary Outcomes

Evaluate the impact of Apollo wearable use on sleep metrics as measured by the Oura Ring device.

Secondary Outcomes

Evaluate the impact of Apollo wearable use on cardiovascular metrics as measured by the Oura Ring device.


Open-Label Trial of Apollo in Veterans with Post-Traumatic Stress Disorder (PTSD)

Partner

Rocky Mountain VA Hospital, MIRECC for Suicide Prevention

Status

Recruitment Open (Local participants only)

Sample Size

100

Population

Veterans (age 18-65) eligible to receive care by a VA provider

Primary Outcomes

To test the acceptability and feasibility of the Apollo wearable system for managing symptoms in Veterans with PTSD.

Secondary Outcomes

Inflammatory biomarkers, microbiome, stress response gene expression.


Open-Label Clinical Trial of Apollo to Sustain Remission in Treatment-Resistant PTSD following MDMA-Assisted Therapy

Partner

The Board of Medicine

Status

Recruitment Open (Eligible Remote Participants)

Sample Size

200

Population

Any past participant in a MAPS trial of MDMA-assisted therapy who has completed their final follow up period with MAPS, including participants who received placebo and those who dropped out of the study prior to completion, are eligible to participate.

Primary Outcomes

To examine how use of Apollo can influence PTSD symptoms and remission rates over two years after participation in any MAPS trial of MDMA-assisted therapy.


Double-Blind Randomized Placebo-Controlled Trial of Apollo to Reduce Symptoms of ADHD/ADD

Partner

Michigan State University

Status

Recruitment Open (Local participants only)

Sample Size

100

Population

Children and Young Adults (7-17yo)

Primary Outcomes

To examine the effect of wearing Apollo on symptoms associated with ADHD.

Secondary Outcomes

To examine the effect of wearing Apollo on medication use associated with ADHD.


Remote Real World Observational Sleep Study of the Apollo Wearable

Partner

The Board of Medicine

Status

Recruitment Open (Eligible Remote participants)

Sample Size

6000

Population

Any Apollo wearable and Oura Ring user over age 18

Primary Outcomes

To examine the impact of Apollo usage on users' sleep and cardiovascular metrics as measured by validated survey tools and biometric data captured by the Oura Ring.


Open-Label Trial of Apollo for Treatment-Resistant Cancer Pain and Fatigue

Partner

University of Pittsburgh Medical Center

Status

Recruitment Open (Local participants only)

Sample Size

30

Population

Adults age 18-100 with metastatic breast cancer and fatigue

Primary Outcomes

To evaluate the efficacy and tolerability of the Apollo device in the management of fatigue and pain in patients with Metastatic Breast Cancer.


Open-Label Trial of Apollo to Reduce Fatigue in Systemic Sclerosis

Partner

University of Pittsburgh Medical Center

Status

Recruitment Open (Local participants only)

Sample Size

30

Population

Adults over age 18 with systemic sclerosis and fatigue

Primary Outcomes

The purpose of this study is to learn about the effect of Apollo on fatigue, Raynaud symptoms, depression, quality of life, and disease symptoms in patients with systemic sclerosis.


A Wearable Wrist-Worn Nerve Stimulator for Remediating Persistent Symptoms in Adolescents with PCS and Chronic Headache

Partner

University of South Carolina & The Board of Medicine

Status

Recruitment Open(Local Participants)

Sample Size

100

Population

Adolescents with PCS and Chronic Headache

Primary Outcomes

Examine how Apollo wearable use in participants with Post Concussion Syndrome (PCS) impacts their treatment outcomes in clinic and overall symptomatology.


Open-Label Trial of Apollo to Improve Recovery and Prevent Burnout in Physicians

Partner

University of Pittsburgh & University of California Los Angeles

Status

Recruitment Open at UPMC

Sample Size

500

Population

Any physician currently in clinical practice or training at UPMC or UCLA

Primary Outcomes

This study is aimed at evaluating the impact of HRV-improving technology on physician well being, namely subjective and objective measures of stress and recovery among physicians.

Secondary Outcomes

Biometric data on cardiovascular fitness (HR/HRV) and sleep collected from Oura Ring and Apple Health.


Continuous Blood Pressure Monitoring with and without Vibratory Ankle Bracelet in Human Volunteers

Partner

BioActive (BAS)

Status

Recruitment Open

Sample Size

21

Population

General population age 18-65

Primary Outcomes

To examine if the Apollo wearable will reliably improve cardiovascular function in healthy subjects.

Secondary Outcomes

To examine whether heart rate variability (HRV) will change before and after the vibratory stimulation by Apollo.

If you鈥檙e a participant in an active study and you need assistance, please contact us at research@apolloneuro.com. To see if you are eligible to join our research, learn more here.